Shruthi Mahalingaiah, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polycystic Ovary Syndrome | 10 | 2024 | 376 | 4.360 |
Why?
|
Menstrual Cycle | 9 | 2024 | 536 | 2.960 |
Why?
|
Endocrine Disruptors | 7 | 2022 | 263 | 2.790 |
Why?
|
Cosmetics | 3 | 2023 | 102 | 2.020 |
Why?
|
Environmental Exposure | 17 | 2024 | 4412 | 1.640 |
Why?
|
Menstruation Disturbances | 5 | 2024 | 143 | 1.610 |
Why?
|
Air Pollution | 9 | 2023 | 2314 | 1.500 |
Why?
|
Air Pollutants | 11 | 2023 | 2842 | 1.480 |
Why?
|
Fertilization in Vitro | 7 | 2022 | 1292 | 1.370 |
Why?
|
Reproductive Techniques, Assisted | 2 | 2024 | 497 | 1.360 |
Why?
|
Environmental Pollutants | 7 | 2024 | 1268 | 1.320 |
Why?
|
Infertility, Female | 3 | 2024 | 759 | 1.290 |
Why?
|
Menarche | 2 | 2024 | 529 | 1.240 |
Why?
|
Fertility | 5 | 2024 | 773 | 1.200 |
Why?
|
Abortion, Spontaneous | 4 | 2019 | 530 | 1.130 |
Why?
|
Phenols | 3 | 2019 | 514 | 1.030 |
Why?
|
Ovulation Induction | 2 | 2024 | 277 | 1.000 |
Why?
|
Malus | 2 | 2022 | 50 | 0.990 |
Why?
|
Pregnancy Rate | 3 | 2017 | 649 | 0.980 |
Why?
|
Hair Preparations | 2 | 2021 | 32 | 0.940 |
Why?
|
Benzophenones | 1 | 2024 | 58 | 0.920 |
Why?
|
Ovary | 2 | 2019 | 958 | 0.870 |
Why?
|
Phthalic Acids | 3 | 2024 | 477 | 0.860 |
Why?
|
Menstruation | 2 | 2023 | 307 | 0.860 |
Why?
|
Tetrachloroethylene | 3 | 2020 | 7 | 0.860 |
Why?
|
Hypoparathyroidism | 1 | 2024 | 136 | 0.860 |
Why?
|
Information Seeking Behavior | 1 | 2024 | 116 | 0.850 |
Why?
|
Ovarian Hyperstimulation Syndrome | 1 | 2022 | 47 | 0.810 |
Why?
|
Pregnancy Outcome | 6 | 2023 | 2907 | 0.720 |
Why?
|
Benzhydryl Compounds | 3 | 2019 | 900 | 0.710 |
Why?
|
Pregnancy | 26 | 2024 | 29742 | 0.700 |
Why?
|
Hirsutism | 1 | 2020 | 68 | 0.700 |
Why?
|
Endometriosis | 3 | 2022 | 874 | 0.660 |
Why?
|
Leiomyoma | 2 | 2014 | 654 | 0.640 |
Why?
|
Premature Birth | 4 | 2024 | 1771 | 0.640 |
Why?
|
Water Pollutants, Chemical | 3 | 2020 | 354 | 0.630 |
Why?
|
Prenatal Exposure Delayed Effects | 4 | 2020 | 2496 | 0.580 |
Why?
|
Ecosystem | 1 | 2021 | 487 | 0.580 |
Why?
|
Women's Health | 4 | 2024 | 2057 | 0.550 |
Why?
|
Female | 63 | 2024 | 390323 | 0.540 |
Why?
|
Gastroesophageal Reflux | 1 | 2023 | 816 | 0.530 |
Why?
|
Nurses | 3 | 2022 | 2467 | 0.510 |
Why?
|
Metformin | 1 | 2023 | 907 | 0.510 |
Why?
|
Reproduction | 2 | 2018 | 646 | 0.500 |
Why?
|
Metabolome | 1 | 2022 | 982 | 0.500 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2015 | 105 | 0.500 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1185 | 0.490 |
Why?
|
Uterine Neoplasms | 2 | 2014 | 1439 | 0.490 |
Why?
|
Infertility | 1 | 2020 | 655 | 0.450 |
Why?
|
Qualitative Research | 1 | 2024 | 2976 | 0.440 |
Why?
|
Diethylstilbestrol | 1 | 2013 | 88 | 0.440 |
Why?
|
Menopause | 3 | 2021 | 1639 | 0.440 |
Why?
|
Fetal Development | 1 | 2019 | 766 | 0.440 |
Why?
|
Vehicle Emissions | 2 | 2017 | 655 | 0.440 |
Why?
|
Maternal Exposure | 3 | 2024 | 1045 | 0.430 |
Why?
|
Metabolomics | 1 | 2022 | 1629 | 0.420 |
Why?
|
Particulate Matter | 7 | 2023 | 2556 | 0.420 |
Why?
|
Plastics | 1 | 2012 | 115 | 0.400 |
Why?
|
Ovulation | 2 | 2023 | 181 | 0.390 |
Why?
|
Humans | 63 | 2024 | 758406 | 0.370 |
Why?
|
Adult | 34 | 2024 | 219935 | 0.360 |
Why?
|
Culture Media | 1 | 2012 | 899 | 0.350 |
Why?
|
Pilot Projects | 5 | 2023 | 8553 | 0.340 |
Why?
|
Electronic Health Records | 2 | 2024 | 4761 | 0.300 |
Why?
|
Cohort Studies | 13 | 2024 | 41256 | 0.290 |
Why?
|
Follicle Stimulating Hormone | 3 | 2024 | 725 | 0.280 |
Why?
|
Young Adult | 13 | 2024 | 58808 | 0.280 |
Why?
|
Luteinizing Hormone | 3 | 2024 | 820 | 0.270 |
Why?
|
Preconception Care | 2 | 2017 | 139 | 0.260 |
Why?
|
Anti-Mullerian Hormone | 3 | 2022 | 407 | 0.240 |
Why?
|
North America | 2 | 2020 | 1276 | 0.240 |
Why?
|
Alabama | 1 | 2024 | 106 | 0.230 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2796 | 0.230 |
Why?
|
Placenta Diseases | 2 | 2017 | 196 | 0.220 |
Why?
|
Educational Status | 1 | 2011 | 2513 | 0.220 |
Why?
|
Inositol | 1 | 2024 | 215 | 0.220 |
Why?
|
Soaps | 1 | 2023 | 29 | 0.220 |
Why?
|
Hypocalcemia | 1 | 2024 | 199 | 0.210 |
Why?
|
United States | 10 | 2024 | 72136 | 0.210 |
Why?
|
Perimenopause | 1 | 2024 | 141 | 0.210 |
Why?
|
Menorrhagia | 1 | 2022 | 59 | 0.210 |
Why?
|
Contraceptive Agents | 1 | 2023 | 145 | 0.200 |
Why?
|
Adolescent | 10 | 2024 | 87892 | 0.200 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2022 | 116 | 0.200 |
Why?
|
Hypercalcemia | 1 | 2024 | 421 | 0.190 |
Why?
|
Prospective Studies | 9 | 2024 | 54137 | 0.190 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 12075 | 0.190 |
Why?
|
Oils | 1 | 2021 | 56 | 0.190 |
Why?
|
Hazardous Substances | 1 | 2022 | 152 | 0.190 |
Why?
|
Fertilization | 1 | 2022 | 197 | 0.190 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12440 | 0.190 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 25956 | 0.180 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2023 | 362 | 0.180 |
Why?
|
Progesterone | 2 | 2024 | 742 | 0.180 |
Why?
|
Progestins | 1 | 2022 | 302 | 0.180 |
Why?
|
Chorionic Gonadotropin | 1 | 2022 | 457 | 0.180 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15399 | 0.180 |
Why?
|
Oocyte Retrieval | 1 | 2021 | 158 | 0.180 |
Why?
|
Age Factors | 3 | 2024 | 18358 | 0.170 |
Why?
|
Ultraviolet Rays | 2 | 2022 | 1076 | 0.170 |
Why?
|
Endometrium | 1 | 2022 | 403 | 0.170 |
Why?
|
Patient Selection | 1 | 2011 | 4244 | 0.160 |
Why?
|
New York | 1 | 2021 | 874 | 0.160 |
Why?
|
Fluorocarbons | 1 | 2024 | 489 | 0.160 |
Why?
|
Chromatography, Liquid | 1 | 2022 | 986 | 0.160 |
Why?
|
Infant, Newborn | 6 | 2024 | 26183 | 0.150 |
Why?
|
Self Report | 2 | 2020 | 3714 | 0.150 |
Why?
|
Infant, Low Birth Weight | 1 | 2023 | 859 | 0.150 |
Why?
|
Embryo Transfer | 1 | 2022 | 522 | 0.150 |
Why?
|
Climate Change | 1 | 2024 | 488 | 0.150 |
Why?
|
Boston | 5 | 2021 | 9304 | 0.150 |
Why?
|
Seasons | 1 | 2023 | 1519 | 0.150 |
Why?
|
Acetaminophen | 1 | 2021 | 552 | 0.140 |
Why?
|
Oocytes | 1 | 2022 | 1165 | 0.140 |
Why?
|
Cryopreservation | 1 | 2022 | 717 | 0.140 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2022 | 1153 | 0.140 |
Why?
|
Time Factors | 5 | 2024 | 39872 | 0.130 |
Why?
|
Health Surveys | 2 | 2017 | 4064 | 0.130 |
Why?
|
Residence Characteristics | 2 | 2017 | 2058 | 0.130 |
Why?
|
Middle Aged | 10 | 2024 | 219568 | 0.130 |
Why?
|
Pregnancy Trimester, First | 2 | 2024 | 908 | 0.120 |
Why?
|
Stillbirth | 2 | 2017 | 368 | 0.120 |
Why?
|
Longevity | 1 | 2022 | 1050 | 0.120 |
Why?
|
Mass Spectrometry | 1 | 2022 | 2189 | 0.120 |
Why?
|
Body Mass Index | 2 | 2024 | 12876 | 0.120 |
Why?
|
Birth Weight | 1 | 2023 | 2097 | 0.120 |
Why?
|
Massachusetts | 5 | 2021 | 8823 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2024 | 3992 | 0.120 |
Why?
|
Estrogens | 1 | 2021 | 1520 | 0.120 |
Why?
|
ROC Curve | 1 | 2022 | 3563 | 0.110 |
Why?
|
Canada | 2 | 2016 | 2111 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2048 | 0.110 |
Why?
|
Retrospective Studies | 7 | 2024 | 80168 | 0.110 |
Why?
|
Patient Compliance | 2 | 2015 | 2685 | 0.110 |
Why?
|
Ectogenesis | 1 | 2012 | 8 | 0.110 |
Why?
|
Prolactin | 2 | 2021 | 621 | 0.110 |
Why?
|
Embryo Implantation | 2 | 2011 | 270 | 0.100 |
Why?
|
Forecasting | 1 | 2022 | 2923 | 0.100 |
Why?
|
Logistic Models | 2 | 2022 | 13276 | 0.100 |
Why?
|
Counseling | 1 | 2020 | 1541 | 0.100 |
Why?
|
Bariatric Surgery | 1 | 2022 | 986 | 0.100 |
Why?
|
Bone Remodeling | 1 | 2015 | 579 | 0.100 |
Why?
|
DDT | 1 | 2011 | 31 | 0.100 |
Why?
|
Hexachlorobenzene | 1 | 2011 | 27 | 0.100 |
Why?
|
Limit of Detection | 1 | 2012 | 270 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2024 | 14490 | 0.100 |
Why?
|
Particle Size | 1 | 2016 | 1641 | 0.100 |
Why?
|
Caffeine | 1 | 2016 | 701 | 0.100 |
Why?
|
Dichlorodiphenyl Dichloroethylene | 1 | 2011 | 85 | 0.100 |
Why?
|
Suction | 1 | 2012 | 262 | 0.090 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 266 | 0.090 |
Why?
|
Calcium | 1 | 2024 | 5721 | 0.090 |
Why?
|
Incidence | 4 | 2020 | 21272 | 0.090 |
Why?
|
Solubility | 1 | 2012 | 1088 | 0.090 |
Why?
|
Hypoglycemic Agents | 1 | 2023 | 3069 | 0.090 |
Why?
|
Drug Design | 1 | 2015 | 1049 | 0.090 |
Why?
|
Hormone Replacement Therapy | 1 | 2015 | 754 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2551 | 0.080 |
Why?
|
Age of Onset | 1 | 2016 | 3298 | 0.080 |
Why?
|
Animals | 7 | 2023 | 167768 | 0.080 |
Why?
|
Polychlorinated Biphenyls | 1 | 2011 | 236 | 0.080 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2012 | 1539 | 0.080 |
Why?
|
Internet | 1 | 2021 | 3082 | 0.080 |
Why?
|
Child | 4 | 2024 | 79818 | 0.080 |
Why?
|
Blood Pressure | 1 | 2024 | 8451 | 0.080 |
Why?
|
Androgens | 1 | 2015 | 1291 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1659 | 0.070 |
Why?
|
Environmental Monitoring | 1 | 2014 | 1445 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6354 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10146 | 0.070 |
Why?
|
Obesity | 3 | 2024 | 12870 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20055 | 0.070 |
Why?
|
Tandem Mass Spectrometry | 1 | 2012 | 1186 | 0.070 |
Why?
|
Risk Factors | 5 | 2021 | 73809 | 0.070 |
Why?
|
Comprehension | 1 | 2011 | 619 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39059 | 0.060 |
Why?
|
T-Box Domain Proteins | 1 | 2008 | 468 | 0.060 |
Why?
|
Macaca mulatta | 2 | 2022 | 2316 | 0.060 |
Why?
|
Life Style | 1 | 2015 | 3886 | 0.060 |
Why?
|
Algorithms | 1 | 2024 | 13961 | 0.050 |
Why?
|
Chronic Disease | 1 | 2018 | 9267 | 0.050 |
Why?
|
Male | 9 | 2023 | 358747 | 0.050 |
Why?
|
Risk Assessment | 2 | 2016 | 23884 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12096 | 0.050 |
Why?
|
Benzene | 1 | 2022 | 106 | 0.050 |
Why?
|
Testosterone | 2 | 2024 | 2471 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8611 | 0.050 |
Why?
|
Alkanesulfonic Acids | 1 | 2024 | 199 | 0.050 |
Why?
|
Pregnancy Trimester, Third | 1 | 2024 | 582 | 0.050 |
Why?
|
Pregnancy Trimester, Second | 1 | 2024 | 732 | 0.050 |
Why?
|
Sperm Count | 1 | 2022 | 228 | 0.050 |
Why?
|
Follicular Fluid | 1 | 2021 | 92 | 0.050 |
Why?
|
Linear Models | 1 | 2011 | 5862 | 0.050 |
Why?
|
Patient Education as Topic | 1 | 2011 | 2307 | 0.050 |
Why?
|
Formaldehyde | 1 | 2022 | 358 | 0.050 |
Why?
|
Sperm Motility | 1 | 2022 | 265 | 0.040 |
Why?
|
Gonadal Steroid Hormones | 1 | 2024 | 701 | 0.040 |
Why?
|
Semen Analysis | 1 | 2022 | 234 | 0.040 |
Why?
|
Perioperative Period | 1 | 2021 | 262 | 0.040 |
Why?
|
Periodicity | 1 | 2021 | 348 | 0.040 |
Why?
|
Semen | 1 | 2022 | 346 | 0.040 |
Why?
|
Testis | 1 | 2022 | 794 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 6953 | 0.040 |
Why?
|
Thyrotropin | 1 | 2021 | 832 | 0.040 |
Why?
|
Hot Temperature | 1 | 2024 | 1434 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2011 | 2942 | 0.040 |
Why?
|
Placebos | 1 | 2021 | 1661 | 0.040 |
Why?
|
Estradiol | 1 | 2024 | 1933 | 0.030 |
Why?
|
Abruptio Placentae | 1 | 2017 | 118 | 0.030 |
Why?
|
Uterine Hemorrhage | 1 | 2017 | 242 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2008 | 4353 | 0.030 |
Why?
|
Infant, Small for Gestational Age | 1 | 2017 | 460 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2322 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1702 | 0.030 |
Why?
|
Quality of Life | 1 | 2015 | 13285 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 22029 | 0.030 |
Why?
|
Demography | 1 | 2018 | 1651 | 0.030 |
Why?
|
Vitamins | 1 | 2021 | 1632 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14641 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3565 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2024 | 3671 | 0.020 |
Why?
|
Pain Measurement | 1 | 2021 | 3527 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 2021 | 1721 | 0.020 |
Why?
|
Beverages | 1 | 2016 | 819 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2024 | 3941 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 11892 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2011 | 956 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2008 | 365 | 0.020 |
Why?
|
Pre-Eclampsia | 1 | 2017 | 1227 | 0.020 |
Why?
|
STAT5 Transcription Factor | 1 | 2008 | 263 | 0.020 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 173 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12262 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7378 | 0.020 |
Why?
|
Janus Kinase 2 | 1 | 2008 | 537 | 0.020 |
Why?
|
Signal Transduction | 1 | 2008 | 23342 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2011 | 64378 | 0.010 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2008 | 788 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10495 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7980 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2014 | 3561 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6157 | 0.010 |
Why?
|
Infant | 1 | 2023 | 36055 | 0.010 |
Why?
|
Smoking | 1 | 2018 | 9051 | 0.010 |
Why?
|
Prevalence | 1 | 2018 | 15651 | 0.010 |
Why?
|
Blotting, Western | 1 | 2008 | 5031 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2008 | 6209 | 0.010 |
Why?
|
Child, Preschool | 1 | 2018 | 42062 | 0.010 |
Why?
|
Cell Line | 1 | 2008 | 15591 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2018 | 58683 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2008 | 18940 | 0.010 |
Why?
|
Aged | 1 | 2018 | 168218 | 0.000 |
Why?
|
Mice | 1 | 2008 | 81101 | 0.000 |
Why?
|